ReviewDiagnostics (Basel, Switzerland)2022
Parkinson's Disease Subtyping Using Clinical Features and Biomarkers: Literature Review and Preliminary Study of Subtype Clustering.
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Longitudinal brain morphometry in Parkinson's disease clinical subtypes: Distinct signatures forecast behavioral change within subtypes.Parkinsonism & related disorders · 2026Article
- PDualNet: a deep learning framework for joint prediction of Parkinson's disease progression subtype and MDS-UPDRS scores.Scientific reports · 2025Article
- Identifying brain degeneration patterns in early-stage Parkinson's disease: a multimodal MRI study.NPJ Parkinson's disease · 2025Article
- Transcriptome signatures of human neural stem cells derived from LRRK2 gene therapeutic cells.Scientific reports · 2025Article
- Data-Driven Subtypes of Parkinson Disease Based on Dopamine Responsiveness.CNS neuroscience & therapeutics · 2025Article
- Digital gait biomarkers in Parkinson's disease: susceptibility/risk, progression, response to exercise, and prognosis.NPJ Parkinson's disease · 2025Review
- Unsupervised subtyping of motor dysfunction of Parkinson's disease and its structural brain imaging correlates.Neuroimage. Reports · 2025Article
- Transcriptomics profiling of Parkinson's disease progression subtypes reveals distinctive patterns of gene expression.Journal of central nervous system disease · 2025Article
- First steps matter: gait initiation reveals emotion-driven motor compensation in Parkinson's disease.Brain communications · 2025Article
- Neuroimaging-based data-driven subtypes of spatiotemporal atrophy due to Parkinson's disease.Brain communications · 2025Article
- The Role of Non-Invasive Brain Modulation in Identifying Disease Biomarkers for Diagnostic and Therapeutic Purposes in Parkinsonism.Brain sciences · 2024Review
- Microstructural alterations in white matter and related neurobiology based on the new clinical subtypes of Parkinson's disease.Frontiers in neuroscience · 2024Article
- Functional neural networks stratify Parkinson's disease patients across the spectrum of cognitive impairment.Brain and behavior · 2024Article
- Study of the gut microbiome in Egyptian patients with Parkinson's Disease.BMC microbiology · 2023Article
- Two distinct trajectories of clinical and neurodegeneration events in Parkinson's disease.NPJ Parkinson's disease · 2023Article
- Structural and functional differences of the thalamus between drug-naïve Parkinson's disease motor subtypes.Frontiers in neurology · 2023Article
- Insights into Human-Induced Pluripotent Stem Cell-Derived Astrocytes in Neurodegenerative Disorders.Biomolecules · 2022Review
- Precision medicine for Parkinson's disease: The subtyping challenge.Frontiers in aging neuroscience · 2022Article
- Genetic architecture of Parkinson's disease subtypes - Review of the literature.Frontiers in aging neuroscience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The second most common progressive neurodegenerative disorder, Parkinson's disease (PD), is characterized by a broad spectrum of symptoms that are associated with its progression. Several studies have attempted to classify PD according to its clinical manifestations and establish objective biomarkers for early diagnosis and for predicting the prognosis of the disease. Recent comprehensive research on the classification of PD using clinical phenotypes has included factors such as dominance, severity, and prognosis of motor and non-motor symptoms and biomarkers. Additionally, neuroimaging studies have attempted to reveal the pathological substrate for motor symptoms. Genetic and transcriptomic studies have contributed to our understanding of the underlying molecular pathogenic mechanisms and provided a basis for classifying PD. Moreover, an understanding of the heterogeneity of clinical manifestations in PD is required for a personalized medicine approach. Herein, we discuss the possible subtypes of PD based on clinical features, neuroimaging, and biomarkers for developing personalized medicine for PD. In addition, we conduct a preliminary clustering using gait features for subtyping PD. We believe that subtyping may facilitate the development of therapeutic strategies for PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.